 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 8 | 2 | 10 | | 1991 | 5 | 3 | 8 | | 1992 | 10 | 5 | 15 | | 1993 | 4 | 6 | 10 | | 1994 | 1 | 4 | 5 | | 1995 | 8 | 2 | 10 | | 1996 | 24 | 3 | 27 | | 1997 | 9 | 5 | 14 | | 1998 | 5 | 8 | 13 | | 1999 | 10 | 7 | 17 | | 2000 | 12 | 10 | 22 | | 2001 | 17 | 5 | 22 | | 2002 | 11 | 8 | 19 | | 2003 | 13 | 10 | 23 | | 2004 | 15 | 10 | 25 | | 2005 | 17 | 12 | 29 | | 2006 | 9 | 5 | 14 | | 2007 | 10 | 9 | 19 | | 2008 | 12 | 14 | 26 | | 2009 | 17 | 13 | 30 | | 2010 | 19 | 8 | 27 | | 2011 | 14 | 12 | 26 | | 2012 | 10 | 7 | 17 | | 2013 | 21 | 9 | 30 | | 2014 | 18 | 14 | 32 | | 2015 | 16 | 6 | 22 | | 2016 | 10 | 15 | 25 | | 2017 | 16 | 7 | 23 | | 2018 | 10 | 7 | 17 | | 2019 | 10 | 8 | 18 | | 2020 | 6 | 4 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020 09 14; 9:CD013206.
-
Martin Paez Y, Bennett JL, Subramanian PS, Pelak VS. Considerations for the Treatment of Inflammatory Neuro-Ophthalmologic Disorders During the COVID-19 Pandemic. J Neuroophthalmol. 2020 09; 40(3):305-314.
-
Friedman KG, Jone PN. Update on the Management of Kawasaki Disease. Pediatr Clin North Am. 2020 10; 67(5):811-819.
-
Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020 07 14; 95(2):e111-e120.
-
Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, Belman A, Benson L, Chitnis T, Gorman M, Goyal MS, Harris Y, Krupp L, Lotze T, Mar S, Moodley M, Ness J, Rodriguez M, Rose J, Schreiner T, Tillema JM, Waltz M, Casper TC, Waubant E. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020 07; 88(1):42-55.
-
Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020 05; 19(5):391-401.
-
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 05; 19(5):402-412.
-
Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020 04; 104(4):881-887.
-
Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020 04; 5(4):393-405.
-
Feldman AG, Hsu EK, Mack CL. The Importance of Prioritizing Pre and Posttransplant Immunizations in an Era of Vaccine Refusal and Epidemic Outbreaks. Transplantation. 2020 01; 104(1):33-38.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|